Oculis Holding AG (OCS) Long-Term Investments (2021 - 2025)
Oculis Holding AG's (OCS) quarterly Long-Term Investments came in at $239.1 million in Q4 2025, up 9.61% year-on-year from $218.1 million in Q4 2024, and up 9.61% quarter-over-quarter from $218.1 million in Q4 2024.
Oculis Holding AG (OCS) Long-Term Investments (2021 - 2025) Analysis & Trends
Oculis Holding AG's Long-Term Investments history runs 5 years deep, the most recent figure standing at $239.1 million for Q4 2025.
- On a quarterly basis, Long-Term Investments rose 9.61% year-over-year to $239.1 million in Q4 2025; TTM through Dec 2025 was $239.1 million, a 9.61% increase from a year earlier, with the FY2025 full-year figure at $230.5 million, up 6.11% from the prior year.
- Long-Term Investments grew to $239.1 million in Q4 2025 per OCS's latest filing, from $218.1 million in the prior quarter.
- Across five years, Long-Term Investments topped out at $239.1 million in Q4 2025 and bottomed at $51901.1 in Q4 2022.
- The 5-year median for Long-Term Investments is $215.4 million (2023), against an average of $134.5 million.
- Across the five-year window, Long-Term Investments decreased 7.97% in 2022 and soared 414920.6% in 2023, its largest moves.
- Year by year, Long-Term Investments stood at $56394.1 in 2021, then slipped by 7.97% to $51901.1 in 2022, then surged by 414920.6% to $215.4 million in 2023, then gained by 1.26% to $218.1 million in 2024, then rose by 9.61% to $239.1 million in 2025.
- Per Business Quant, the three latest OCS Long-Term Investments figures stand at $239.1 million (Q4 2025), $218.1 million (Q4 2024), and $215.4 million (Q4 2023).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 505,194.89 |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.75 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 9.79 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn | 22.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 239.06 Mn |
| Dec 31, 2024 | 218.11 Mn |
| Dec 31, 2023 | 215.40 Mn |
| Dec 31, 2022 | 51,901.10 |
| Dec 31, 2021 | 56,394.11 |